Crystagen

Crystagen is a synthetic tripeptide (Glutamic acid-Aspartic acid-Arginine, Glu-Asp-Arg) developed within Professor Vladimir Khavinson's peptide bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the same family of short peptide bioregulators that includes Epithalon (Ala-Glu-Asp-Gly), Thymalin, Cortagen, Livagen, Pancragen, and other organ-targeted tetrapeptides and tripeptides.

The Khavinson bioregulator paradigm is based on the hypothesis that short (2-4 amino acid) peptides derived from specific organ tissues can regulate gene expression in target organs by serving as short regulatory peptides that interact with chromatin — specifically with gene promoter regions that contain complementary nucleotide sequences to the peptide-encoding codons.

Key research publications from Khavinson's group demonstrate that short peptides can: 1. Bind DNA and RNA with sequence selectivity related to their amino acid composition 2. Modulate histone methylation and acetylation patterns (epigenetic regulation) 3. Increase expression of specific genes in target organ tissue

Crystagen is specifically formulated for the brain and nervous system based on the tissue from which the founding peptide sequence was derived. Research from the Khavinson group suggests it may support neuronal gene expression and protein synthesis, with proposed applications in age-related cognitive decline and neuroprotection.

It should be noted that while the Khavinson research group has published extensively in the Russian scientific literature, these findings have limited independent validation in international peer-reviewed journals. The mechanistic plausibility of short peptide-DNA interactions has been explored computationally and in cell-free systems, but the clinical translation remains an active area of research.